BEACON CRC: A randomized, 3-Arm, phase 3 study of Encorafenib (ENCO) and Cetuximab (CETUX) with or without Binimetinib (BINI) versus choice of either Irinotecan or FOLFIRI plus Cetuximab in BRAF V600E-mutant metastatic colorectal cancerJayesh Desai,Scott Kopetz,Axel Grothey,Eric Van Cutsem,Rona Yaeger,Harpreet Wasan,Takayuki Yoshino,Fortunato Ciardello,Ashwin Gollerkeri,Kati Maharry,Fotios Loupakis,Yong Sang Hong,Neeltje Steeghs,Tormod Kyrre Guren,Hendrik-Tobias Arkenau,Pilar Garcia Alfonso,Timothy Price,Andrew Strickland,Niall Tebbutt,Christos Karapetis,Lorraine Chantrill,Felicity Murphy,Victor Sandor,Janna Christy-Bittel,Lisa Anderson,Josep TaberneroASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY（2019）引用 0|浏览2暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
